MiNK Therapeutics Announces That Late-Breaking Phase 1 Data For Its Allogeneic iNKT Cell Therapy, AgenT-797, Will Be Presented At 40th Annual SITC Meeting Nov 7–9, 2025

Author: Benzinga Newsdesk | October 30, 2025 08:03am

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that late-breaking data demonstrating durable clinical activity of AgenT-797, allo-INKTs, in advanced solid tumors will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 7–9, 2025, in National Harbor, Maryland.

The presentation, titled "AgenT-797, an Allogeneic iNKT Cell Therapy, Demonstrates Durable Clinical Activity in Solid Tumors: Updated Phase 1 Findings" (LBA #1344), will highlight updated safety and efficacy results from the company's ongoing Phase 1 study of AgenT-797 in patients with advanced solid tumors. AgenT-797 is an off-the-shelf iNKT cell therapy designed to reprogram the immune system and overcome resistance to conventional immunotherapies.

Presentation details:

• Title: AgenT-797, an Allogeneic iNKT Cell Therapy, Demonstrates Durable Clinical Activity in Solid Tumors: Updated Phase 1 Findings
• Author: Dr. Benjamin Garmezy, Assistant Director of Genitourinary Research for Sarah Cannon Research Institute at SCRI Oncology Partners
• Abstract Number: 1344
• Location: Prince George ABC Exhibit Halls, Gaylord National Resort & Convention Center, National Harbor, MD
• Dates/Time: Saturday, November 8th | poster attendance from 12:15–1:45 p.m. ET and 5:10–6:35 p.m. ET
   

Posted In: INKT